For research use only. Not for therapeutic Use.
Breviscapine(CAT: M024948) is a natural flavonoid extract derived from Erigeron breviscapus, primarily composed of scutellarin and apigenin-7-O-glucuronide. It exhibits multiple pharmacological effects, including vasodilation, anti-inflammatory, antioxidant, and neuroprotective activities. Breviscapine enhances cerebral blood flow and protects against ischemic injury by inhibiting platelet aggregation, reducing oxidative stress, and modulating inflammatory pathways. It has been studied for its potential in treating cerebrovascular diseases, ischemic stroke, and cognitive impairment. Given its effects on vascular and neural health, Breviscapine is most relevant to Cardiovascular Disease Research and Neurological Disease Research, particularly in the context of stroke, vascular dementia, and neurodegenerative conditions.
| Catalog Number | M024948 |
| CAS Number | 116122-36-2 |
| Molecular Formula | C54H84N16O21 |
| Purity | ≥95% |
| IUPAC Name | 6-[5,6-dihydroxy-2-(4-hydroxyphenyl)-4-oxochromen-7-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid |
| InChI | InChI=1S/C21H18O12/c22-8-3-1-7(2-4-8)10-5-9(23)13-11(31-10)6-12(14(24)15(13)25)32-21-18(28)16(26)17(27)19(33-21)20(29)30/h1-6,16-19,21-22,24-28H,(H,29,30) |
| InChIKey | DJSISFGPUUYILV-UHFFFAOYSA-N |
| SMILES | C1=CC(=CC=C1C2=CC(=O)C3=C(C(=C(C=C3O2)OC4C(C(C(C(O4)C(=O)O)O)O)O)O)O)O |
